Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Human Blastoid-Based Platform for Post-Implantation IVF Optimization and Therapeutic Screening

Ziel

Since the first successful IVF birth in 1978, the technology has become a cornerstone of assisted
reproduction, driven by the trend toward delayed parenthood. While IVF now accounts for roughly
5% of births in Europe, its overall efficiency remains low, with only about 25% of cycles resulting in a
live birth. A major bottleneck is the high rate of failure during implantation. Due to the limited
availability of human embryos and ethical restrictions, IVF optimization has historically relied on
mouse models. However, while pre-implantation development is similar between mice and humans,
their post-implantation trajectories diverge significantly, limiting their translational relevance. This
highlights the urgent need for a reliable, ethical, and predictive model of early human development
after implantation. Under the ERC-CoG program, we developed human blastoids, blastocyst-like
structures that accurately mimic key features of pre-implantation human embryogenesis. The present ERC-PoC project will translate
this platform into a pre-commercial application by screening compounds to improve IVF outcomes.
Our expected deliverables include: (i) a validated blastoid-based screening platform, (ii) patented natural compounds with therapeutic potential for IVF, and (iii) a
business and IP framework for investors, partners, and funding bodies.

Wissenschaftliches Gebiet (EuroSciVoc)

Dieses Projekt wurde noch nicht bei EuroSciVoc klassifiziert.
Schlagen Sie die Wissenschaftsbereiche vor, die Ihrer Einschätzung nach besonders relevant sind, und helfen Sie uns, unseren Klassifizierungsdienst zu verbessern.

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) ERC-2025-POC

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Gastgebende Einrichtung

INSTITUT FUER MOLEKULARE BIOTECHNOLOGIE GMBH
Netto-EU-Beitrag
€ 150 000,00
Adresse
DR BOHRGASSE 3
1030 Wien
Österreich
Region
Ostösterreich Wien Wien
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
Keine Daten

Begünstigte (1)